HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Mark Wheatley Selected Research

Hemorrhage

1/2010A novel thromboxane A2 receptor D304N variant that abrogates ligand binding in a patient with a bleeding diathesis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Mark Wheatley Research Topics

Disease

2Neoplasms (Cancer)
02/2024 - 01/2009
1Hemorrhage
01/2010
1Disease Susceptibility (Diathesis)
01/2010
1Small Cell Lung Carcinoma (Small Cell Lung Cancer)
01/2009
1Seizures (Absence Seizure)
12/2005
1Pain (Aches)
12/2005

Drug/Important Bio-Agent (IBA)

2LigandsIBA
01/2010 - 12/2005
1Doxorubicin (Adriamycin)FDA LinkGeneric
02/2024
1Prostaglandin H2 Thromboxane A2 ReceptorsIBA
01/2010
1Arginine Vasopressin (Argipressin)IBA
01/2009
1Gastrin-Releasing PeptideIBA
01/2009
1substance P (6-11)IBA
01/2009

Therapy/Procedure

1Drug Therapy (Chemotherapy)
02/2024
1Therapeutics
01/2009